TGF-β dominant negative receptor modified TILs

TGF-β dominant negative receptor modified TILs are tumor-infiltrating lymphocytes (TILs) that have been genetically engineered to express a dominant-negative transforming growth factor-beta (TGF-β) receptor, most often a truncated TGF-β receptor II (TGF-βRII) that lacks intracellular signaling capacity. This modification renders TILs resistant to TGF-β-mediated immunosuppression within the tumor microenvironment. TGF-β is a potent immunosuppressive cytokine widely present in many cancers and contributes to immune evasion, T cell exhaustion, and resistance to immunotherapy. By preventing TGF-β signaling in TILs, this approach enhances their proliferation, cytokine secretion, persistence, infiltration, and anti-tumor activity in the presence of TGF-β, as demonstrated in multiple preclinical and early clinical settings. These engineered TILs are being explored primarily for use in the treatment of advanced solid tumors, such as prostate cancer and glioblastoma, to overcome the immunosuppressive tumor microenvironment and improve therapeutic efficacy[3][1].

Other names

dnTGFβR-modified TILs